| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 35 | 2020 | 261 | 4.070 |
Why?
|
| Polymorphism, Genetic | 16 | 2020 | 179 | 2.240 |
Why?
|
| Polymorphism, Single Nucleotide | 48 | 2019 | 1050 | 2.020 |
Why?
|
| African Americans | 20 | 2020 | 1335 | 1.020 |
Why?
|
| Anti-Asthmatic Agents | 6 | 2014 | 37 | 1.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2020 | 116 | 0.920 |
Why?
|
| Receptors, Adrenergic, beta-2 | 7 | 2014 | 25 | 0.910 |
Why?
|
| Interleukin-6 | 5 | 2019 | 224 | 0.900 |
Why?
|
| Genetic Predisposition to Disease | 23 | 2019 | 821 | 0.850 |
Why?
|
| European Continental Ancestry Group | 18 | 2020 | 1076 | 0.820 |
Why?
|
| Lung | 8 | 2020 | 263 | 0.800 |
Why?
|
| Prostatic Neoplasms | 13 | 2012 | 489 | 0.760 |
Why?
|
| Kidney Failure, Chronic | 6 | 2018 | 534 | 0.680 |
Why?
|
| Humans | 92 | 2020 | 32274 | 0.670 |
Why?
|
| Genotype | 21 | 2020 | 702 | 0.650 |
Why?
|
| Genetic Variation | 8 | 2015 | 248 | 0.650 |
Why?
|
| Pharmacogenetics | 7 | 2012 | 29 | 0.640 |
Why?
|
| Apolipoproteins | 4 | 2016 | 194 | 0.630 |
Why?
|
| Lipoproteins, HDL | 4 | 2016 | 250 | 0.620 |
Why?
|
| Hispanic Americans | 11 | 2020 | 772 | 0.570 |
Why?
|
| Middle Aged | 48 | 2020 | 11848 | 0.550 |
Why?
|
| GTPase-Activating Proteins | 2 | 2017 | 5 | 0.540 |
Why?
|
| Male | 60 | 2020 | 19437 | 0.530 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2012 | 64 | 0.530 |
Why?
|
| Adult | 39 | 2020 | 9256 | 0.530 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2019 | 14 | 0.520 |
Why?
|
| Forced Expiratory Volume | 12 | 2020 | 81 | 0.520 |
Why?
|
| Adrenergic beta-Agonists | 7 | 2014 | 31 | 0.500 |
Why?
|
| Fatty Acids | 1 | 2017 | 100 | 0.500 |
Why?
|
| Haplotypes | 14 | 2011 | 213 | 0.470 |
Why?
|
| DNA Methylation | 7 | 2017 | 144 | 0.460 |
Why?
|
| Respiratory System | 1 | 2015 | 11 | 0.450 |
Why?
|
| Lupus Nephritis | 1 | 2015 | 29 | 0.450 |
Why?
|
| Linkage Disequilibrium | 12 | 2014 | 181 | 0.450 |
Why?
|
| Mitochondria | 1 | 2017 | 211 | 0.450 |
Why?
|
| Molecular Motor Proteins | 1 | 2015 | 59 | 0.450 |
Why?
|
| Genome-Wide Association Study | 11 | 2018 | 543 | 0.450 |
Why?
|
| Myosin Heavy Chains | 1 | 2015 | 84 | 0.440 |
Why?
|
| Muscle, Smooth | 2 | 2015 | 152 | 0.440 |
Why?
|
| Trachea | 1 | 2015 | 53 | 0.440 |
Why?
|
| Mutation | 9 | 2017 | 497 | 0.440 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 314 | 0.430 |
Why?
|
| Female | 47 | 2020 | 19942 | 0.430 |
Why?
|
| Signal Transduction | 9 | 2020 | 727 | 0.430 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2020 | 40 | 0.430 |
Why?
|
| Insulin Resistance | 6 | 2017 | 458 | 0.420 |
Why?
|
| Sequence Analysis, DNA | 11 | 2017 | 132 | 0.420 |
Why?
|
| Gene Expression Regulation | 8 | 2020 | 478 | 0.420 |
Why?
|
| Disease Progression | 6 | 2019 | 591 | 0.410 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2004 | 15 | 0.400 |
Why?
|
| Phenotype | 14 | 2020 | 621 | 0.400 |
Why?
|
| Transcription Factors | 3 | 2011 | 183 | 0.390 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 3 | 2018 | 36 | 0.390 |
Why?
|
| Severity of Illness Index | 9 | 2019 | 853 | 0.390 |
Why?
|
| Gene Expression | 3 | 2012 | 345 | 0.370 |
Why?
|
| Case-Control Studies | 15 | 2019 | 854 | 0.370 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 293 | 0.370 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2009 | 8 | 0.350 |
Why?
|
| Epithelial Cells | 3 | 2019 | 132 | 0.350 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2016 | 215 | 0.330 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2010 | 81 | 0.320 |
Why?
|
| Immunoglobulin E | 6 | 2017 | 36 | 0.310 |
Why?
|
| Aged | 25 | 2020 | 10260 | 0.310 |
Why?
|
| Fluocinolone Acetonide | 1 | 2009 | 5 | 0.300 |
Why?
|
| Albuterol | 4 | 2017 | 17 | 0.290 |
Why?
|
| Bronchodilator Agents | 4 | 2017 | 34 | 0.290 |
Why?
|
| Base Sequence | 8 | 2010 | 252 | 0.290 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 38 | 0.290 |
Why?
|
| Smoking | 3 | 2020 | 505 | 0.280 |
Why?
|
| Adiponectin | 4 | 2017 | 94 | 0.280 |
Why?
|
| Flavoproteins | 1 | 2008 | 6 | 0.270 |
Why?
|
| Trans-Activators | 1 | 2008 | 43 | 0.270 |
Why?
|
| Atherosclerosis | 6 | 2017 | 820 | 0.270 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 46 | 0.270 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 74 | 0.270 |
Why?
|
| Cell Cycle Proteins | 1 | 2008 | 52 | 0.270 |
Why?
|
| Polymerase Chain Reaction | 8 | 2010 | 186 | 0.270 |
Why?
|
| Adolescent | 14 | 2019 | 3517 | 0.260 |
Why?
|
| Promoter Regions, Genetic | 10 | 2014 | 203 | 0.250 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 26 | 0.250 |
Why?
|
| Vital Capacity | 4 | 2020 | 37 | 0.250 |
Why?
|
| Child | 11 | 2019 | 2434 | 0.240 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 3 | 2012 | 5 | 0.240 |
Why?
|
| Animals | 18 | 2020 | 8199 | 0.240 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2016 | 59 | 0.240 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 160 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2009 | 15 | 0.230 |
Why?
|
| Fatty Acid Desaturases | 2 | 2017 | 51 | 0.230 |
Why?
|
| Drug Design | 1 | 2005 | 51 | 0.230 |
Why?
|
| DNA-Binding Proteins | 3 | 2016 | 149 | 0.230 |
Why?
|
| Interleukin-4 | 3 | 2012 | 22 | 0.230 |
Why?
|
| Monocytes | 2 | 2019 | 141 | 0.230 |
Why?
|
| Pharmaceutical Preparations | 1 | 2005 | 38 | 0.220 |
Why?
|
| Ethnic Groups | 2 | 2007 | 450 | 0.220 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 104 | 0.220 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 159 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.210 |
Why?
|
| Phosphoproteins | 2 | 2019 | 54 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| Gene Frequency | 9 | 2017 | 211 | 0.200 |
Why?
|
| Young Adult | 11 | 2020 | 2648 | 0.200 |
Why?
|
| Interleukin-13 | 5 | 2019 | 29 | 0.200 |
Why?
|
| alpha 1-Antitrypsin | 2 | 2020 | 2 | 0.190 |
Why?
|
| Cohort Studies | 7 | 2020 | 1840 | 0.190 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2002 | 5 | 0.190 |
Why?
|
| Alleles | 6 | 2020 | 250 | 0.190 |
Why?
|
| Germ-Line Mutation | 1 | 2002 | 15 | 0.190 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 52 | 0.190 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 32 | 0.180 |
Why?
|
| Cell Proliferation | 5 | 2020 | 603 | 0.180 |
Why?
|
| Proteomics | 2 | 2019 | 97 | 0.170 |
Why?
|
| Obesity | 3 | 2016 | 1111 | 0.170 |
Why?
|
| RNA, Messenger | 5 | 2015 | 499 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2020 | 1437 | 0.170 |
Why?
|
| Drug Resistance | 2 | 2020 | 42 | 0.160 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2020 | 41 | 0.160 |
Why?
|
| Quadriceps Muscle | 1 | 2020 | 29 | 0.160 |
Why?
|
| Sulfones | 1 | 2020 | 23 | 0.160 |
Why?
|
| Indans | 1 | 2020 | 31 | 0.160 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2017 | 24 | 0.160 |
Why?
|
| Progesterone Reductase | 1 | 2020 | 2 | 0.160 |
Why?
|
| Steroid Isomerases | 1 | 2020 | 2 | 0.160 |
Why?
|
| Multienzyme Complexes | 1 | 2020 | 19 | 0.160 |
Why?
|
| Pulmonary Emphysema | 1 | 2020 | 23 | 0.160 |
Why?
|
| Prediabetic State | 1 | 2020 | 76 | 0.150 |
Why?
|
| Arginase | 2 | 2010 | 5 | 0.150 |
Why?
|
| Loss of Heterozygosity | 3 | 2010 | 20 | 0.150 |
Why?
|
| Chromosome Mapping | 5 | 2009 | 188 | 0.150 |
Why?
|
| Inflammation | 4 | 2017 | 506 | 0.150 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 423 | 0.150 |
Why?
|
| Metabolomics | 1 | 2019 | 63 | 0.150 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2019 | 61 | 0.150 |
Why?
|
| Glycoproteins | 1 | 2019 | 34 | 0.150 |
Why?
|
| Family Health | 2 | 2017 | 73 | 0.150 |
Why?
|
| Myeloid Cells | 1 | 2019 | 39 | 0.150 |
Why?
|
| Genomics | 1 | 2019 | 89 | 0.150 |
Why?
|
| DNA Mutational Analysis | 5 | 2017 | 69 | 0.140 |
Why?
|
| Glioblastoma | 1 | 2020 | 159 | 0.140 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2019 | 37 | 0.140 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 3898 | 0.140 |
Why?
|
| Whole-Body Irradiation | 1 | 2019 | 58 | 0.140 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 256 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2020 | 146 | 0.140 |
Why?
|
| DNA Primers | 4 | 2009 | 84 | 0.140 |
Why?
|
| Nephritis | 2 | 2015 | 15 | 0.140 |
Why?
|
| Blood Glucose | 1 | 2020 | 484 | 0.140 |
Why?
|
| Genetic Loci | 2 | 2018 | 143 | 0.140 |
Why?
|
| Bronchi | 2 | 2016 | 33 | 0.140 |
Why?
|
| Proteins | 2 | 2010 | 149 | 0.140 |
Why?
|
| Risk Factors | 8 | 2019 | 3934 | 0.140 |
Why?
|
| Phosphorylation | 3 | 2015 | 250 | 0.140 |
Why?
|
| Registries | 1 | 2019 | 294 | 0.140 |
Why?
|
| Glomerulonephritis | 1 | 2018 | 19 | 0.140 |
Why?
|
| Multigene Family | 1 | 2017 | 50 | 0.130 |
Why?
|
| Membrane Proteins | 2 | 2011 | 243 | 0.130 |
Why?
|
| Graft Rejection | 1 | 2018 | 236 | 0.130 |
Why?
|
| Bulbar Palsy, Progressive | 1 | 2017 | 2 | 0.130 |
Why?
|
| Gelsolin | 1 | 2017 | 2 | 0.130 |
Why?
|
| Amyloidosis, Familial | 1 | 2017 | 2 | 0.130 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 20 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 246 | 0.130 |
Why?
|
| Kidney Diseases | 2 | 2016 | 243 | 0.130 |
Why?
|
| Kidney Neoplasms | 2 | 2010 | 200 | 0.130 |
Why?
|
| Blotting, Western | 2 | 2015 | 299 | 0.130 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 11 | 0.130 |
Why?
|
| Receptors, Cell Surface | 2 | 2014 | 78 | 0.120 |
Why?
|
| Laminin | 1 | 2016 | 13 | 0.120 |
Why?
|
| NFI Transcription Factors | 1 | 2016 | 13 | 0.120 |
Why?
|
| Blood Proteins | 1 | 2016 | 19 | 0.120 |
Why?
|
| Family | 2 | 2014 | 112 | 0.120 |
Why?
|
| Emphysema | 1 | 2016 | 12 | 0.120 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 274 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 297 | 0.120 |
Why?
|
| Cells, Cultured | 5 | 2019 | 839 | 0.120 |
Why?
|
| Transcription, Genetic | 3 | 2019 | 140 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 131 | 0.120 |
Why?
|
| Lod Score | 4 | 2017 | 68 | 0.120 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2015 | 10 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 595 | 0.120 |
Why?
|
| Hypertension, Renal | 1 | 2015 | 27 | 0.110 |
Why?
|
| Anemia, Sickle Cell | 1 | 2015 | 42 | 0.110 |
Why?
|
| Molecular Sequence Data | 3 | 2008 | 359 | 0.110 |
Why?
|
| Mice | 7 | 2020 | 2571 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 219 | 0.110 |
Why?
|
| Lectins | 1 | 2015 | 11 | 0.110 |
Why?
|
| 3' Untranslated Regions | 3 | 2012 | 25 | 0.110 |
Why?
|
| Adipokines | 1 | 2015 | 11 | 0.110 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2014 | 5 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 637 | 0.110 |
Why?
|
| Bronchial Hyperreactivity | 3 | 2011 | 16 | 0.110 |
Why?
|
| Microsatellite Repeats | 1 | 2014 | 22 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 189 | 0.110 |
Why?
|
| Cytokines | 1 | 2016 | 237 | 0.110 |
Why?
|
| Epigenesis, Genetic | 2 | 2013 | 109 | 0.110 |
Why?
|
| Macrophages | 2 | 2014 | 207 | 0.110 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 1083 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 83 | 0.110 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 490 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 443 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2016 | 320 | 0.100 |
Why?
|
| Prostate-Specific Antigen | 2 | 2003 | 59 | 0.100 |
Why?
|
| Th1 Cells | 1 | 2013 | 24 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2017 | 81 | 0.100 |
Why?
|
| Receptors, Immunologic | 2 | 2002 | 24 | 0.100 |
Why?
|
| Actinin | 1 | 2012 | 4 | 0.090 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2012 | 4 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 46 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2010 | 113 | 0.090 |
Why?
|
| Receptors, Androgen | 2 | 2003 | 44 | 0.090 |
Why?
|
| Receptors, Estrogen | 2 | 2002 | 104 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 520 | 0.090 |
Why?
|
| Cell Movement | 3 | 2020 | 167 | 0.090 |
Why?
|
| Open Reading Frames | 2 | 2008 | 21 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2012 | 116 | 0.080 |
Why?
|
| Soybean Proteins | 1 | 2011 | 101 | 0.080 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2002 | 216 | 0.080 |
Why?
|
| Wilms Tumor | 1 | 2010 | 15 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 111 | 0.080 |
Why?
|
| Respiratory Function Tests | 3 | 2018 | 93 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2011 | 144 | 0.080 |
Why?
|
| CpG Islands | 3 | 2017 | 44 | 0.080 |
Why?
|
| Genetic Association Studies | 3 | 2015 | 146 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2007 | 258 | 0.080 |
Why?
|
| Exons | 2 | 2012 | 52 | 0.080 |
Why?
|
| Time Factors | 4 | 2019 | 2204 | 0.080 |
Why?
|
| ADAM Proteins | 1 | 2009 | 12 | 0.070 |
Why?
|
| Administration, Inhalation | 1 | 2009 | 43 | 0.070 |
Why?
|
| Netherlands | 2 | 2009 | 25 | 0.070 |
Why?
|
| Histocompatibility Antigens | 1 | 2008 | 11 | 0.070 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2008 | 15 | 0.070 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2008 | 27 | 0.070 |
Why?
|
| Endotoxins | 1 | 2008 | 37 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2008 | 45 | 0.070 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2008 | 5 | 0.070 |
Why?
|
| Jews | 1 | 2008 | 1 | 0.070 |
Why?
|
| ARNTL Transcription Factors | 1 | 2008 | 1 | 0.070 |
Why?
|
| Cryptochromes | 1 | 2008 | 1 | 0.070 |
Why?
|
| Period Circadian Proteins | 1 | 2008 | 1 | 0.070 |
Why?
|
| Indians, South American | 1 | 2008 | 2 | 0.070 |
Why?
|
| CLOCK Proteins | 1 | 2008 | 2 | 0.070 |
Why?
|
| Eosinophils | 2 | 2019 | 32 | 0.070 |
Why?
|
| Leukotriene Antagonists | 1 | 2008 | 2 | 0.070 |
Why?
|
| Receptors, Leukotriene | 1 | 2008 | 3 | 0.070 |
Why?
|
| Cholinergic Antagonists | 1 | 2008 | 10 | 0.070 |
Why?
|
| Mexico | 1 | 2008 | 47 | 0.070 |
Why?
|
| Poly C | 1 | 2007 | 1 | 0.070 |
Why?
|
| Receptors, Muscarinic | 1 | 2008 | 21 | 0.070 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2008 | 101 | 0.070 |
Why?
|
| Indians, North American | 1 | 2008 | 75 | 0.070 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 24 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2007 | 23 | 0.070 |
Why?
|
| Macaca mulatta | 2 | 2019 | 340 | 0.070 |
Why?
|
| African Continental Ancestry Group | 4 | 2016 | 338 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 63 | 0.070 |
Why?
|
| Neoplasms, Experimental | 2 | 2007 | 33 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2007 | 131 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 140 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2012 | 3416 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2008 | 149 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2007 | 20 | 0.060 |
Why?
|
| Cholesterol, HDL | 2 | 2011 | 181 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 729 | 0.060 |
Why?
|
| Mast Cells | 1 | 2006 | 13 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2007 | 108 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 541 | 0.060 |
Why?
|
| Patient Selection | 1 | 2008 | 272 | 0.060 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2006 | 10 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 38 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2006 | 37 | 0.060 |
Why?
|
| Trinucleotide Repeats | 2 | 2003 | 9 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 543 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 2 | 2018 | 47 | 0.060 |
Why?
|
| Nitric Oxide | 2 | 2017 | 121 | 0.060 |
Why?
|
| Prekallikrein | 1 | 2004 | 1 | 0.050 |
Why?
|
| Codon, Nonsense | 1 | 2004 | 4 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2004 | 40 | 0.050 |
Why?
|
| Population Groups | 1 | 2004 | 8 | 0.050 |
Why?
|
| Genetic Markers | 4 | 2012 | 124 | 0.050 |
Why?
|
| United States | 3 | 2014 | 4072 | 0.050 |
Why?
|
| Lipids | 2 | 2017 | 253 | 0.050 |
Why?
|
| Prognosis | 2 | 2018 | 1534 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 792 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2012 | 456 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2003 | 12 | 0.050 |
Why?
|
| Allelic Imbalance | 1 | 2003 | 5 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2003 | 48 | 0.050 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2003 | 9 | 0.050 |
Why?
|
| Postmenopause | 2 | 2002 | 424 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2002 | 5 | 0.050 |
Why?
|
| Immunoconjugates | 1 | 2002 | 10 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 27 | 0.050 |
Why?
|
| E-Selectin | 1 | 2002 | 20 | 0.050 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2002 | 6 | 0.050 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 1 | 2002 | 2 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1300 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1479 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2002 | 227 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 45 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2002 | 226 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 114 | 0.040 |
Why?
|
| Maximal Midexpiratory Flow Rate | 1 | 2020 | 1 | 0.040 |
Why?
|
| Isoelectric Focusing | 1 | 2020 | 4 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 126 | 0.040 |
Why?
|
| Kidney | 2 | 2018 | 521 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2014 | 454 | 0.040 |
Why?
|
| Liver | 2 | 2014 | 492 | 0.040 |
Why?
|
| Heterozygote | 1 | 2020 | 60 | 0.040 |
Why?
|
| Androgens | 1 | 2020 | 30 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2020 | 285 | 0.040 |
Why?
|
| Wnt Proteins | 2 | 2010 | 17 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2019 | 16 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2019 | 17 | 0.040 |
Why?
|
| Macaca fascicularis | 2 | 2011 | 542 | 0.040 |
Why?
|
| Computational Biology | 1 | 2019 | 99 | 0.040 |
Why?
|
| Cell Line | 2 | 2012 | 454 | 0.040 |
Why?
|
| Homozygote | 2 | 2012 | 52 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 83 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 264 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 158 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 15 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2017 | 55 | 0.030 |
Why?
|
| Demography | 1 | 2017 | 101 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2017 | 11 | 0.030 |
Why?
|
| Lymphopenia | 1 | 2017 | 11 | 0.030 |
Why?
|
| Leucovorin | 1 | 2017 | 19 | 0.030 |
Why?
|
| Hypokalemia | 1 | 2017 | 16 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 30 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2018 | 186 | 0.030 |
Why?
|
| Neutropenia | 1 | 2017 | 24 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 60 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 62 | 0.030 |
Why?
|
| Graft Survival | 1 | 2018 | 293 | 0.030 |
Why?
|
| Sulfides | 1 | 2017 | 27 | 0.030 |
Why?
|
| Caprylates | 1 | 2017 | 27 | 0.030 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 13 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 41 | 0.030 |
Why?
|
| Camptothecin | 1 | 2017 | 45 | 0.030 |
Why?
|
| Breath Tests | 1 | 2017 | 18 | 0.030 |
Why?
|
| Sputum | 1 | 2017 | 17 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2017 | 44 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 50 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 61 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2017 | 79 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2017 | 85 | 0.030 |
Why?
|
| Aging | 1 | 2003 | 942 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 174 | 0.030 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 17 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 287 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 14 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 757 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 140 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 126 | 0.030 |
Why?
|
| Sepsis | 1 | 2017 | 164 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1241 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 565 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 907 | 0.030 |
Why?
|
| Airway Remodeling | 1 | 2015 | 5 | 0.030 |
Why?
|
| Transfection | 2 | 2007 | 204 | 0.030 |
Why?
|
| Databases, Nucleic Acid | 1 | 2014 | 5 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 883 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2014 | 15 | 0.030 |
Why?
|
| Metabolism | 1 | 2014 | 7 | 0.030 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2014 | 8 | 0.030 |
Why?
|
| Cattle | 1 | 1995 | 116 | 0.030 |
Why?
|
| Chemokines, CC | 1 | 2014 | 6 | 0.030 |
Why?
|
| Azacitidine | 1 | 2014 | 27 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2014 | 9 | 0.030 |
Why?
|
| Chloride Channels | 1 | 2014 | 7 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2014 | 51 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2014 | 100 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2014 | 54 | 0.030 |
Why?
|
| alpha-Linolenic Acid | 1 | 2014 | 12 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2014 | 59 | 0.030 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2014 | 13 | 0.030 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2014 | 36 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 247 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 252 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 863 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2013 | 10 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2013 | 26 | 0.020 |
Why?
|
| Pedigree | 2 | 2004 | 136 | 0.020 |
Why?
|
| Luciferases | 2 | 2003 | 33 | 0.020 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2013 | 4 | 0.020 |
Why?
|
| STAT4 Transcription Factor | 1 | 2013 | 15 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2013 | 29 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 2316 | 0.020 |
Why?
|
| Nuclear Pore | 1 | 2012 | 2 | 0.020 |
Why?
|
| Scavenger Receptors, Class A | 2 | 2002 | 4 | 0.020 |
Why?
|
| Receptors, Scavenger | 2 | 2002 | 6 | 0.020 |
Why?
|
| Prednisone | 1 | 2012 | 69 | 0.020 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 1158 | 0.020 |
Why?
|
| Transcriptional Activation | 2 | 2002 | 46 | 0.020 |
Why?
|
| Neoplasms | 1 | 2019 | 754 | 0.020 |
Why?
|
| Placebos | 1 | 2012 | 68 | 0.020 |
Why?
|
| Genes, Homeobox | 1 | 2011 | 5 | 0.020 |
Why?
|
| Caseins | 1 | 2011 | 21 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 276 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 179 | 0.020 |
Why?
|
| DNA | 2 | 2003 | 223 | 0.020 |
Why?
|
| Muscles | 1 | 2011 | 69 | 0.020 |
Why?
|
| Thrombospondins | 1 | 2011 | 6 | 0.020 |
Why?
|
| Saint Kitts and Nevis | 1 | 2011 | 4 | 0.020 |
Why?
|
| DNA, Intergenic | 1 | 2011 | 10 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 23 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2011 | 16 | 0.020 |
Why?
|
| Isoflavones | 1 | 2011 | 103 | 0.020 |
Why?
|
| Genes, Wilms Tumor | 1 | 2010 | 6 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 475 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 565 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2010 | 6 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 83 | 0.020 |
Why?
|
| COS Cells | 1 | 2010 | 33 | 0.020 |
Why?
|
| Colorado | 1 | 2010 | 43 | 0.020 |
Why?
|
| Texas | 1 | 2010 | 40 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2010 | 28 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 70 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2011 | 60 | 0.020 |
Why?
|
| Phylogeny | 1 | 2010 | 67 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 717 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 1895 | 0.020 |
Why?
|
| Cholesterol | 1 | 2011 | 262 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1223 | 0.020 |
Why?
|
| Adiposity | 1 | 2010 | 190 | 0.020 |
Why?
|
| Histones | 1 | 2008 | 50 | 0.020 |
Why?
|
| RNA Editing | 1 | 2008 | 3 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 78 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2008 | 46 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2008 | 121 | 0.020 |
Why?
|
| Linear Models | 1 | 2009 | 425 | 0.020 |
Why?
|
| RNA Stability | 1 | 2007 | 4 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2008 | 68 | 0.020 |
Why?
|
| Smad Proteins | 1 | 2007 | 7 | 0.020 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2007 | 6 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2007 | 15 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2007 | 4 | 0.020 |
Why?
|
| ras Proteins | 1 | 2007 | 10 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2008 | 94 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 193 | 0.020 |
Why?
|
| Logistic Models | 1 | 2009 | 743 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 257 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 157 | 0.010 |
Why?
|
| Codon, Terminator | 1 | 2004 | 2 | 0.010 |
Why?
|
| Serum | 1 | 2004 | 14 | 0.010 |
Why?
|
| Solubility | 1 | 2004 | 39 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 150 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 2004 | 23 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 14 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2003 | 9 | 0.010 |
Why?
|
| Electrophoresis | 1 | 2003 | 8 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 1425 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 74 | 0.010 |
Why?
|
| Palpation | 1 | 2003 | 9 | 0.010 |
Why?
|
| Response Elements | 1 | 2003 | 16 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2003 | 102 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2003 | 90 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 196 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 183 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 40 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 146 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 112 | 0.010 |
Why?
|
| DNA-Formamidopyrimidine Glycosylase | 1 | 2002 | 1 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2002 | 97 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 471 | 0.010 |
Why?
|
| Estrogen Receptor alpha | 1 | 2002 | 50 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2002 | 37 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2002 | 47 | 0.010 |
Why?
|
| Triglycerides | 1 | 2002 | 235 | 0.010 |
Why?
|
| Prevalence | 1 | 2003 | 955 | 0.010 |
Why?
|
| Cosmids | 1 | 1995 | 2 | 0.010 |
Why?
|
| Metaphase | 1 | 1995 | 2 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1995 | 3 | 0.010 |
Why?
|
| Gene Library | 1 | 1995 | 7 | 0.010 |
Why?
|
| DNA Probes | 1 | 1995 | 18 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1995 | 43 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1995 | 93 | 0.010 |
Why?
|